http://www.fda.gov/cder/drug/infopage/celebrex/celebrex-ptsk.htm
Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Based on emerging information, including preliminary reports from one of several long term National Institutes of Health (NIH) prevention studies, the risk of cardiovascular events may be increased in patients receiving Celebrex. FDA will be analyzing all available information from these studies to determine whether additional regulatory action is needed.